Romiplostim in Patients undergoing Hematopoietic Stem Cell Transplantation: Results of a Phase I/II multicenter Trial.

Persisting severe thrombocytopenia more than 6 weeks after allogeneic stem cell transplantation is a common problem associated with adverse prognosis. Peffault de Latour et al report the results of the first trial of the thrombopoietin mimetic, romiplostim, in this setting, demonstrating recovery of platelet counts in 18 of 24 patients.

[1]  X. Mao,et al.  Successful treatment of secondary poor graft function post allogeneic hematopoietic stem cell transplantation with eltrombopag , 2018, Journal of Hematology & Oncology.

[2]  Samip R. Master,et al.  Use of Eltrombopag in Improving Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation , 2018, Case Reports in Oncology.

[3]  A. Clemmons,et al.  Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients , 2017, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[4]  S. Fuji,et al.  Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  A. Vekhoff,et al.  Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation , 2015, Bone Marrow Transplantation.

[6]  T. Lamparelli,et al.  CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  B. Dumitriu,et al.  Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. , 2014, Blood.

[8]  J. Friedberg,et al.  A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  B. Dumitriu,et al.  Eltrombopag and improved hematopoiesis in refractory aplastic anemia. , 2012, The New England journal of medicine.

[10]  Yuhchyau Chen,et al.  Use of eltrombopag, a thrombopoietin receptor agonist, in post‐transplantation thrombocytopenia , 2012, American journal of hematology.

[11]  B. Bain,et al.  Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. , 2009, Blood.

[12]  R. Yamazaki,et al.  Prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation: associations with impaired platelet production and increased platelet turnover , 2006, Bone Marrow Transplantation.

[13]  F. Appelbaum,et al.  The Problem of Thrombocytopenia after Hematopoietic Stem Cell Transplantation , 1996, Stem cells.